AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard care.Baxdrostat (Baxfendy) is the first aldosterone synthase inhibitor approved to treat uncontrolled high blood pressure in people with primary aldosteronism, a hormonal disorder that promotes sodium and water retention, according to a company press release.

AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard care.Baxdrostat (Baxfendy) is the first aldosterone synthase…

AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with…

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in…

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off. | After an…